17th January 2019
- Aptamer Group announces collaboration with AstraZeneca
- Cancer Biomarker Capture and Elution by Cell Specific Aptamers
- Laboratory and Office expansion
- Interesting applications in glioblastoma and hepatocellular carcinoma (HCC) biomarker aptamers
With lots of new data ongoing for multiple applications in the commercial and academic space the Aptamer Group would like to share with you information monthly that may be of interest for your research and business goals.
The goal of this succinct but informative email is to keep you updated on aptamer research both at Aptamer Group and in general in applications such as bio and cell based assay development, biosensors, flow cytometry, bioprocess and other in vivo applications.
As always, we would love to hear from you to discuss how aptamers can be utilised as the preferred affinity/binding molecules in your research, diagnostics, drug discovery and drug development programs.
Novel Solutions – Cancer Biomarker Capture and Elution by Cell Specific Aptamers
Alternative to Antibodies and Immunoprecipitation
- Unknown biomarkers can be identified
- Tailored to application capture and elution
- Multiple biomarkers identified simultaneously
Figure 1: Sliver stained SDS-PAGE gel showing the binding and elution of the unknown biomarker expressed by prostate cancer cells. For both aptamer positive (right of Ladder) and aptamer negative beads (left of Ladder), unbound, final washes and elutions were collected. The streptavidin band is highlighted by a black arrow and the unknown biomarker in red.
In Review and News AstraZeneca Collaboration
Aptamer Group Announces Agreement with AstraZeneca to Explore Next-Generation Drug Delivery Devices
Aptamer Group on January 7, 2019 announced it has signed an agreement with AstraZeneca to explore the potential of using aptamer technology to target the kidney. The two-year agreement will give AstraZeneca use of Aptamer Group’s proprietary technology to explore the feasibility of developing the next generation of drug delivery vehicles, called Aptamer Drug Conjugates (ApDCs).
This collaborative project, which brings together the platform technology developed at Aptamer Group and AstraZeneca’s leadership in Cardiovascular, Renal and Metabolism (CVRM) therapy development and expertise in drug discovery and development, aims to use ApDCs to enable targeted delivery specifically to the kidney.
In Review and News
Biotech business Aptamer Group has reached an agreement with York Science Park to support its future expansion.
Wu et. al. describes their approach to developing and detecting glioblastoma biomarker aptamers from whole cell SELEX in body fluids
Dong et. al describe Hepatocellular Carcinoma Cell (HCC) minimal fragment aptamers in flow cytometry and in vivo imaging applications